Navigation Links
Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30'
Date:10/9/2007

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced that Andrea Matthews (age 25), manager of its Scientific Programs, was selected by Mass High Tech for its "People to Watch Under 30."

"We are proud to have a young, successful individual like Andrea as part of our team," said Dr. Keith O. Elliston, president and CEO at Genstruct. "She has been a go-getter ever since she started at Genstruct during college. With her strong business, technology and scientific acumen, Andrea serves as a valued translator between our scientific and development teams. She not only shows significant initiative in advancing her career, but also excels in her personal life by volunteering to help Cambridge-area youth and competing in triathlons."

Ms. Matthews received her B.A. cum laude in biochemistry and molecular biology from Boston University in 2004. As an undergraduate summer student, she began working at Genstruct as the first full-time female employee for the company and the youngest by more than 10 years.

In her role as the manager of Scientific Programs at Genstruct, Ms. Matthews drives the progress of scientific and technology development for the company by prioritizing and managing requests across all of its pharmaceutical research projects. During her four years at Genstruct, she has presented scientific information and successfully gone head-to-head with scientists with more than 20 years of experience.

About Genstruct

Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact:

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. San Diego firm selected for Madison Wi-Fi project
2. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
3. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
4. Can sales outsourcing grow Wisconsin biotechs?
5. Wisconsin biotechs plan Japan trade mission
6. Madison biotechs get Commerce grants
7. Midwest shares in stock-market bloodshed as biotechs falter
8. Technology helps but the best way to reduce Sarbox cost is with people
9. Age of empowered individuals: People power behind robust computing
10. Two-week notices: People are still concerned
11. Power for the people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):